Vilazodone

Overview

Vilazodone, sold under the brand name Viibryd among others, is a medication used to treat major depressive disorder. It is classified as a serotonin modulator and is taken by mouth.[1] WP

Its common side effects include nausea, diarrhea, and trouble sleeping. Serious side effects may include increased suicidal thoughts or actions in those under the age of 25, serotonin syndrome, bleeding, activation of mania or hypomania, pancreatitis, seizures, angle-closure glaucoma, sleep paralysis, and sexual dysfunction.[1][2] WP

Vilazodone may cause a syndrome of inappropriate antidiuretic hormone secretion (SIADH). A withdrawal syndrome may occur if the dose is rapidly decreased. Use during pregnancy and breastfeeding is not generally recommended. It is in the serotonin modulator class of medications and is believed to work both as a selective serotonin reuptake inhibitor (SSRI) and activator of the 5-HT1A receptor.[1][3] WP

Vilazodone was approved for medical use in the United States in 2011 and in Canada in 2018. In 2019, it was the 334th most commonly prescribed medication in the United States, with more than 900 thousand prescriptions. The drug lost patent protection in June 2022 for adults and in July 2023 for pediatrics. Generic versions have been approved by the US Food and Drug Administration.[1][4–8] WP

Uses, dosage and effects

Medical uses

Seven controlled efficacy trials were conducted of vilazodone for treatment of major depressive disorder. Five of these trials showed no significant influence of vilazodone over placebo on depressive symptoms. In the remaining two trials, small but significant advantages of vilazodone over placebo were found. According to these two eight-week trials in adults, vilazodone has an antidepressant response after one week of treatment. After eight weeks it resulted in a 13% greater response than placebo. Remission rates, however, were not significantly different versus placebo.[9][10][11] WP

According to the US Food and Drug Administration (FDA) in 2011, "it is unknown whether vilazodone has any advantages compared to other drugs in the antidepressant class." A 2019 review stated that "present studies do not suggest the superiority of vilazodone compared with other antidepressants."[12][13] WP

Development of vilazodone for generalized anxiety disorder has been stopped as of 2017. While there is tentative evidence of a small benefit in generalized anxiety disorder, there is a high rate of side effects.[14][15] WP

Risks and side effects

Adverse effects

In September 2016, the US Food and Drug Administration (FDA) required a new warning to be added to the prescribing information related to a link between vilazodone and acute pancreatitis and sleep paralysis. In addition, other sleep disturbances such as hypnagogic hallucinations and sleep terrors can occur.[16][17][18] WP

Sleep paralysis is a state, during waking up or falling asleep, in which a person is conscious but experiences full-body paralysis. During an episode, the person may hallucinate (hear, feel, or see things that are not there), which often results in fear. A night terror, also called sleep terror, is a sleep disorder causing feelings of panic or dread. The rate of sleep paralysis adverse events was high enough to merit an FDA warning added to the Viibryd prescription label.[2][17][19][20] WP

In July 2021, the US Food and Drug Administration required a new warning to be added to the prescription label that vilazodone may cause sexual dysfunction. Per the FDA label, sexual dysfunction can include ejaculatory delay or failure, decreased libido, and erectile dysfunction in male patients. In female patients, sexual dysfunction can include decreased libido and delayed or absent orgasm.[2] WP

The most common adverse effects include nausea, diarrhea, vomiting, and insomnia.[21] WP

After a one-year, open-label study assessing the safety and tolerability of vilazodone in people with major depressive disorder, the most common adverse effects were diarrhea (35.7%), nausea (31.6%), and headache (20.0%); greater than 90% of these adverse effects were mild or moderate. In randomized controlled trials, meanwhile, these rates were 28%, 23.4% and 13.3%, respectively. In contrast to other selective serotonin reuptake inhibitors (SSRIs), initial trials showed that vilazodone did not cause decreased sexual desire/function, which often cause people to abandon their use. However, post-marketing experience led the FDA to warn that vilazodone may cause sexual dysfunction.[2][11][22][23] WP⚠ Wikipedia itself has flagged this text: unreliable medical source?.

Pregnancy

Antidepressant exposure (including vilazodone) is associated with shorter average duration of pregnancy (by three days), increased risk of preterm delivery (by 55%), lower birth weight (by 75 g), and lower Apgar scores (by <0.4 points). It is uncertain whether there is an increased rate of septal heart defects among children whose mothers were prescribed an SSRI in early pregnancy.[24–27] WP

Pharmacology

Pharmacodynamics

Vilazodone acts as a serotonin reuptake inhibitor (IC₅₀ = 2.1 nM; Kᵢ = 0.1 nM) and 5-HT1A receptor partial agonist (IC₅₀ = 0.2 nM; IA = ~60–70%). It has negligible affinity for other serotonin receptors such as 5-HT1D, 5-HT2A, and 5-HT2C, as well as the norepinephrine and dopamine transporters (Kᵢ = 56 nM for NET and 37 nM for DAT). A small clinical study found occupancy of the 5-HT1A receptor with vilazodone, whereas occupancy of the SERT by vilazodone in humans does not seem to have been studied. It also possesses negligible, if any, clinically relevant affinity for vesicular monoamine transporter 2 (VMAT2) inhibitor (IC₅₀ (half-maximal inhibitory concentration) = 69 nM).[11][21][28–33] WP

Pharmacokinetics

Vilazodone is best absorbed with food and has a bioavailability of 72% under fed conditions. The Cₘₐₓ increased between 147 and 160% and the AUC increased between 64 and 85% of vilazodone when it was administered with either a fatty or light meal.[34] WP

History

History

It was developed by Merck KGaA and licensed by Clinical Data, a biotech company purchased by Forest Laboratories in 2011.[35] WP

Chemistry

Formula

C26H27N5O2 PC

CAS number

163521-12-8 PC

Molar mass (g/mol)

441.5 PC

IUPAC name (computed by PubChem)

5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide PC

SMILES

C1CN(CCN1CCCCC2=CNC3=C2C=C(C=C3)C#N)C4=CC5=C(C=C4)OC(=C5)C(=O)N PC

InChIKey

SGEGOXDYSFKCPT-UHFFFAOYSA-N PC

PubChem CID

6918314

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Vilazodone Hydrochloride Monograph for Professionals
2. Journal / agency label. July 1, 2021
3. Other Vilazodone (Viibryd) Use During Pregnancy
4. Other Drug Product Database Online Query. April 25, 2012
5. Other Vilazodone - Drug Usage Statistics
6. Other Generic Viibryd Availability
7. Journal / agency Vilazodone: FDA-Approved Drugs
8. Journal / agency 2019 First Generic Drugs Approvals. January 21, 2021
9. Journal / agency Kirsch I. Antidepressants and the Placebo Effect. Zeitschrift für Psychologie. 2014. doi:10.1027/2151-2604/a000176 · PMID 25279271 · PMC4172306
10. Journal / agency Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU. Vilazodone for the Treatment of Depression: An Update. Chonnam Medical Journal. May 2016. doi:10.4068/cmj.2016.52.2.91 · PMID 27231672 · PMC4880584
11. Journal / agency Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU. A review of current evidence for vilazodone in major depressive disorder. International Journal of Psychiatry in Clinical Practice. August 2013. doi:10.3109/13651501.2013.794245 · PMID 23578403
12. Journal / agency Laughren TP, Gobburu J, Temple RJ, Unger EF, Bhattaram A, Dinh PV, Fossom L, Hung HM, Klimek V, Lee JE, Levin RL, Lindberg CY, Mathis M, Rosloff BN, Wang SJ, Wang Y, Yang P, Yu B, Zhang H, Zhang L, Zineh I. Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant. The Journal of Clinical Psychiatry. September 2011. doi:10.4088/JCP.11r06984 · PMID 21951984
13. Journal / agency Stuivenga M, Giltay EJ, Cools O, Roosens L, Neels H, Sabbe B. Evaluation of vilazodone for the treatment of depressive and anxiety disorders. Expert Opinion on Pharmacotherapy. February 2019. doi:10.1080/14656566.2018.1549542 · PMID 30475091
14. Other New Medicines Newsletter
15. Journal / agency Zareifopoulos N, Dylja I. Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis. Asian Journal of Psychiatry. April 2017. doi:10.1016/j.ajp.2017.01.016 · PMID 28483071
16. Journal / agency SUPPLEMENT APPROVAL
17. Journal / agency Jiang Y, Qu Y, Du Z, Ou M, Shen Y, Zhou Q, Tian L, Zhu H. Exploring adverse events of Vilazodone: evidence from the FAERS database. BMC Psychiatry. May 2024. doi:10.1186/s12888-024-05813-0 · PMID 38755677 · PMC11100245
18. Journal / agency Mancano MA. ISMP Adverse Drug Reactions: Influenza Vaccine-Induced Stevens-Johnson Syndrome; Vilazodone-Induced Nightmares; Dabigatran-Induced Pustular Eruptions; Neurotoxic and Cardiotoxic Symptoms After Cannabis Concentrate Exposure; Rosuvastatin-Induced Skin Eruption. Hospital Pharmacy. February 2018. doi:10.1177/0018578717739727 · PMID 29434381 · PMC5805017
19. Other Sleep paralysis. 2017-10-23
20. Journal / agency Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest. November 2014. doi:10.1378/chest.14-0970 · PMID 25367475
21. Journal / agency Viibryd (vilazodone hydrochloride) tablet Viibryd (vilazodone hydrochloride) kit [Forest Laboratories, Inc.]. December 2012
22. Journal / agency Robinson DS, Kajdasz DK, Gallipoli S, Whalen H, Wamil A, Reed CR. A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. Journal of Clinical Psychopharmacology. October 2011. doi:10.1097/JCP.0b013e31822c6741 · PMID 21869687
23. Other FDA approves Clinical Data Inc's antidepressant. January 22, 2011
24. Journal / agency Ross LE, Grigoriadis S, Mamisashvili L, Vonderporten EH, Roerecke M, Rehm J, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry. April 2013. doi:10.1001/jamapsychiatry.2013.684 · PMID 23446732
25. Journal / agency Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR, Vazquez DM. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. Journal of Perinatology. September 2005. doi:10.1038/sj.jp.7211352 · PMID 16015372
26. Journal / agency Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ. September 2009. doi:10.1136/bmj.b3569 · PMID 19776103 · PMC2749925
27. Journal / agency Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM, Mogun H, Levin R, Kowal M, Setoguchi S, Hernández-Díaz S. Antidepressant use in pregnancy and the risk of cardiac defects. The New England Journal of Medicine. June 2014. doi:10.1056/NEJMoa1312828 · PMID 24941178 · PMC4062924
28. Journal / agency Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, Middlemiss DN, Dawson LA. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. European Journal of Pharmacology. March 2005. doi:10.1016/j.ejphar.2005.01.018 · PMID 15740724
29. Journal / agency Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, Manning DR, Lucki I. Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist. The Journal of Pharmacology and Experimental Therapeutics. September 2002. doi:10.1124/jpet.102.034280 · PMID 12183683
30. Journal / agency Dawson LA. The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI?. Expert Opinion on Drug Discovery. December 2013. doi:10.1517/17460441.2013.855195 · PMID 24195711
31. Journal / agency Dawson LA, Watson JM. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neuroscience & Therapeutics. 2009. doi:10.1111/j.1755-5949.2008.00067.x · PMID 19499624 · PMC6493994
32. Journal / agency Choi E, Zmarlicka M, Ehret MJ. Vilazodone: a novel antidepressant. American Journal of Health-System Pharmacy. September 2012. doi:10.2146/ajhp110374 · PMID 22935937
33. Journal / agency Racz R, Kozell LB, Eshleman AJ, Bloom SH, Wolfrum KM, Schmachtenberg JL, Swanson TL, Ngai J, Schutzer WE, Janowsky A, Abbas AI, Stavitskaya L. Evaluation of the Relationship between Vesicular Monoamine Transporter 2 (VMAT2) Inhibition and Neurologic Adverse Events in Approved Drugs. ACS Pharmacology & Translational Science. 22 December 2025. doi:10.1021/acsptsci.5c00538
34. Journal / agency Cruz MP. Vilazodone HCl (Viibryd): A Serotonin Partial Agonist and Reuptake Inhibitor For the Treatment of Major Depressive Disorder. P & T. January 2012. PMID 22346333 · PMC3278186
35. Other Xconomy: Blend Therapeutics Taps Former Clinical Data Chief Fromkin As New CEO. April 13, 2015

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.